Medolife Rx to Present at The 2021 Sequire Cannabis Conference on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST
Medolife Rx, a bioceutical company, announced that Quanta's President, Philip Sands, will present at the 2021 Sequire Cannabis Conference on April 20. Sands will discuss the future development of Medolife and Quanta in the bioceutical sector, emphasizing technology, pharmaceutical research, and consumer wellness products in the CBD market. The conference aims to connect investors with industry leaders. Medolife Rx's clinical programs include Escozine®, a treatment derived from scorpions, being researched for COVID-19 and cancer, highlighting their innovative approach to pharmaceuticals.
- None.
- None.
BURBANK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Quanta’s President and Director Philip Sands will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST.
Sands will discuss how Medolife Rx and Quanta will continue to develop their positions in the bioceutical space. He will further discuss their cutting-edge technology, pharmaceutical research, and the development of consumer wellness products for the CBD industry. Additionally, he will address how the Company is planning to develop pharmaceutical-grade CBD products lines for which it will seek clinical regulatory approvals, focusing on indications such as pain.
“Given his deep history with the Company and expertise on the cannabinoid-based product industry, I am excited to see Mr. Sands present on Medolife and Quanta at this conference,” said Medolife CEO Dr. Arthur Mikaelian. “Medolife and Quanta have had an exciting year, and we plan to use this opportunity to share how we believe we are well-positioned for growth and success in the future. “From capitalizing on our proprietary polarization delivery technology to facility expansions and ongoing sales of our numerous consumer wellness products, there are many opportunities on the horizon for our company and potential investors.”
The Sequire Cannabis Conference is a one-day event that brings together a select group of U.S. investors and leading industry participants in the cannabis space. The event will feature video presentations from more than 15 companies, organized in five tracks for attendees.
For those who cannot attend the live presentation, a video webcast of the presentation will be available. To learn more about the 2021 Squire Cannabis Conference and register to participate, visit https://cannabis-conference.mysequire.com/.
About Medolife Rx
Medolife Rx, Inc. is a global biotechnology company with operations in clinical research, manufacturing, and consumer products. Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. The Company’s lead clinical development programs include Escozine®, a proprietary formulation consisting of small molecule peptides derived from Rhopalurus princeps scorpions, which is amplified by the Company’s polarization technology and is being researched as a treatment of various indications, including COVID-19 and cancer. The Company has completed preclinical safety and efficacy research on Escozine® and is pursuing product registration and drug approval in various countries, including the United States and throughout Latin America.
Through its subsidiary QuantRx, Medolife manufactures and distributes consumer wellness products in high-impact consumer areas such as pain relief, beauty, and general wellness. QuantRx products are designed using Dr. Mikaelian’s polarization technology, which applies advances in quantum biology to increase the potency of active ingredients. Ultimately, Quanta's mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste, and facilitate healthier, more sustainable consumption.
Beyond its own clinical and consumer applications, the polarization technology used by Medolife and its subsidiaries has many potential applications. From potentiating bio-ingredients, to producing more-effective carbon-trapping plants, to transformative anti-aging solutions, Medolife has the opportunity to upend how commercial and pharmaceutical products are made and increase their benefits, while decreasing their chemical concentration.
Forward-Looking Statements
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: This release contains statements that are forward-looking in nature which express the beliefs and expectations of management including statements regarding the Company's expected results of operations or liquidity; statements concerning projections, predictions, expectations, estimates or forecasts as to our business, financial and operational results and future economic performance; and statements of management's goals and objectives and other similar expressions concerning matters that are not historical facts. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "estimate," "plan," "project," "continuing," "ongoing," "expect," "we believe," "we intend," "may," "will," "should," "could," and similar expressions. Such statements are based on current plans, estimates and expectations and involve a number of known and unknown risks, uncertainties and other factors that could cause the Company's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. These factors and additional information are discussed in the Company's filings with the Securities and Exchange Commission and statements in this release should be evaluated in light of these important factors. Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results. Forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update publicly or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.
Contacts:
Phil Sands
https://ir.quantrx.com/
818-659-8052
Kyle Porter
medolife@cmwmedia.com
858-264-6600
FAQ
What is the date and time of the 2021 Sequire Cannabis Conference presentation by Quanta's President?
What will Philip Sands discuss at the Sequire Cannabis Conference?
What is Escozine and how is it related to Medolife Rx?
How does Medolife Rx plan to position itself in the CBD industry?
Where can I watch the presentation if I miss the live event?
